Natera (NASDAQ:NTRA) Insider Sells $595,800.00 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,000 shares of the company’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $198.60, for a total value of $595,800.00. Following the transaction, the insider directly owned 112,061 shares in the company, valued at $22,255,314.60. This represents a 2.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, October 28th, Solomon Moshkevich sold 1,198 shares of Natera stock. The stock was sold at an average price of $191.46, for a total transaction of $229,369.08.
• On Monday, October 27th, Solomon Moshkevich sold 1,008 shares of Natera stock. The stock was sold at an average price of $192.32, for a total transaction of $193,858.56.
• On Tuesday, October 21st, Solomon Moshkevich sold 292 shares of Natera stock. The stock was sold at an average price of $187.95, for a total transaction of $54,881.40.
• On Wednesday, October 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $159.99, for a total transaction of $479,970.00.
• On Tuesday, September 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $166.62, for a total transaction of $499,860.00.
• On Thursday, August 14th, Solomon Moshkevich sold 875 shares of Natera stock. The stock was sold at an average price of $155.46, for a total value of $136,027.50.

Natera Stock Down 0.9%

Shares of NTRA traded down $1.78 on Tuesday, reaching $196.45. The stock had a trading volume of 1,848,962 shares, compared to its average volume of 1,140,512. The firm has a market capitalization of $26.96 billion, a PE ratio of -102.85 and a beta of 1.75. The firm has a 50-day moving average of $175.77 and a 200 day moving average of $162.77. Natera, Inc. has a twelve month low of $122.08 and a twelve month high of $203.23.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The firm had revenue of $546.60 million during the quarter, compared to analyst estimates of $476.84 million. During the same quarter in the prior year, the company earned ($0.30) EPS. The business’s revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Natera

Hedge funds have recently made changes to their positions in the business. Bank of Jackson Hole Trust acquired a new stake in shares of Natera during the first quarter worth $29,000. TCTC Holdings LLC boosted its stake in Natera by 114.8% in the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock worth $33,000 after buying an additional 124 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in Natera by 83.5% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock worth $33,000 after buying an additional 106 shares during the last quarter. Hilltop National Bank acquired a new stake in Natera in the 2nd quarter worth about $33,000. Finally, Oliver Lagore Vanvalin Investment Group acquired a new stake in shares of Natera in the second quarter worth approximately $36,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Royal Bank Of Canada set a $268.00 price objective on shares of Natera and gave the company an “outperform” rating in a research note on Tuesday, September 2nd. Cowen reissued a “buy” rating on shares of Natera in a research note on Friday, August 8th. BNP Paribas upgraded shares of Natera to a “hold” rating and set a $172.00 price target on the stock in a research report on Monday, October 27th. Morgan Stanley reiterated an “overweight” rating and issued a $195.00 price target on shares of Natera in a research report on Sunday, August 10th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $220.00 price target (up from $210.00) on shares of Natera in a research report on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and a consensus price target of $194.89.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.